Credit Suisse First Boston U.s. Executive Advisors, L.p. - Net Worth and Insider Trading

Credit Suisse First Boston U.s. Executive Advisors, L.p. Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Credit Suisse First Boston U.s. Executive Advisors, L.p. owns 3 companies in total, including Sunesis Pharmaceuticals Inc (SNSS) , Cytokinetics Inc (CYTK) , and Viracta Therapeutics Inc (VIRX) .

Click here to see the complete history of Credit Suisse First Boston U.s. Executive Advisors, L.p.’s form 4 insider trades.

Insider Ownership Summary of Credit Suisse First Boston U.s. Executive Advisors, L.p.

Ticker	Comapny	Transaction Date	Type of Owner
SNSS	Sunesis Pharmaceuticals Inc	2005-09-30	10 percent owner
CYTK	Cytokinetics Inc	2004-04-29	10 percent owner
VIRX	Viracta Therapeutics Inc	2005-09-30	10 percent owner

Credit Suisse First Boston U.s. Executive Advisors, L.p. Trading Performance

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Credit Suisse First Boston U.s. Executive Advisors, L.p. Ownership Network

Ownership Network List of Credit Suisse First Boston U.s. Executive Advisors, L.p.

No Data

Ownership Network Relation of Credit Suisse First Boston U.s. Executive Advisors, L.p.

Credit Suisse First Boston U.s. Executive Advisors, L.p. Owned Company Details

What does Sunesis Pharmaceuticals Inc do?

Who are the key executives at Sunesis Pharmaceuticals Inc?

Credit Suisse First Boston U.s. Executive Advisors, L.p. is the 10 percent owner of Sunesis Pharmaceuticals Inc. Other key executives at Sunesis Pharmaceuticals Inc include director & See Remarks Dayton Misfeldt , VP & Finance Tina Gullotta , and See Remarks William P. Quinn .

Sunesis Pharmaceuticals Inc (SNSS) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Sunesis Pharmaceuticals Inc (SNSS) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Sunesis Pharmaceuticals Inc (SNSS) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Sunesis Pharmaceuticals Inc (SNSS)'s detailed insider trading history can be found in Insider Trading Tracker table.

Sunesis Pharmaceuticals Inc Insider Transactions

No Available Data

What does Cytokinetics Inc do?

Who are the key executives at Cytokinetics Inc?

Credit Suisse First Boston U.s. Executive Advisors, L.p. is the 10 percent owner of Cytokinetics Inc. Other key executives at Cytokinetics Inc include SVP Research & Early Dev Fady Ibraham Malik , EVP & Corp. Development & CBO Robert I Blum , and VP & Chief Accounting Officer Robert Wong .

Cytokinetics Inc (CYTK) Insider Trades Summary

Over the past 18 months, Credit Suisse First Boston U.s. Executive Advisors, L.p. made no insider transaction in Cytokinetics Inc (CYTK). Other recent insider transactions involving Cytokinetics Inc (CYTK) include a net sale of 373,500 shares made by Robert I Blum , a net sale of 183,194 shares made by Fady Ibraham Malik , and a net sale of 40,000 shares made by B Lynne Parshall .

In summary, during the past 3 months, insiders sold 137,437 shares of Cytokinetics Inc (CYTK) in total and bought 0 shares, with a net sale of 137,437 shares. During the past 18 months, 658,744 shares of Cytokinetics Inc (CYTK) were sold and 0 shares were bought by its insiders, resulting in a net sale of 658,744 shares.

Cytokinetics Inc (CYTK)'s detailed insider trading history can be found in Insider Trading Tracker table.

Cytokinetics Inc Insider Transactions

No Available Data

What does Viracta Therapeutics Inc do?

Who are the key executives at Viracta Therapeutics Inc?

Credit Suisse First Boston U.s. Executive Advisors, L.p. is the 10 percent owner of Viracta Therapeutics Inc. Other key executives at Viracta Therapeutics Inc include Chief Executive Officer Daniel R. Chevallard , director & President and CEO Mark Rothera , and Chief Medical Officer Darrel P. Cohen .

Viracta Therapeutics Inc (VIRX) Insider Trades Summary

Over the past 18 months, Credit Suisse First Boston U.s. Executive Advisors, L.p. made no insider transaction in Viracta Therapeutics Inc (VIRX). Other recent insider transactions involving Viracta Therapeutics Inc (VIRX) include a net sale of 14,272 shares made by Daniel R. Chevallard , and a net purchase of 100,000 shares made by Mark Rothera .

In summary, during the past 3 months, insiders sold 0 shares of Viracta Therapeutics Inc (VIRX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 14,272 shares of Viracta Therapeutics Inc (VIRX) were sold and 100,000 shares were bought by its insiders, resulting in a net purchase of 85,728 shares.

Viracta Therapeutics Inc (VIRX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Viracta Therapeutics Inc Insider Transactions

No Available Data

Credit Suisse First Boston U.s. Executive Advisors, L.p. Mailing Address

Above is the net worth, insider trading, and ownership report for Credit Suisse First Boston U.s. Executive Advisors, L.p.. You might contact Credit Suisse First Boston U.s. Executive Advisors, L.p. via mailing address: 11 Madison Avenue, New York Ny 10010.

Discussions on Credit Suisse First Boston U.s. Executive Advisors, L.p.

No discussions yet.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.